Cancer patients receiving drugs to lower the risk of anaemia...
Published Tuesday 01 December 2009
Chemotherapy can result in insomnia
Insomnia occurs in approximately three-quarters of cancer patients who have...
Published Tuesday 01 December 2009
Osteoarthritis risk increased by high exercise levels
Men and women in middle age who exercise on a...
Published Monday 30 November 2009
Cancer genome changes increase cervical cancer relapse risk
Patients with cervical cancer are three to four times more...
Published Sunday 29 November 2009
More Medical News
HPV & Cervical Cancer
Please note- The EPG HPV and Cervical Cancer Knowledge Centre is for Doctors and other Healthcare Professionals.
Worldwide, every two minutes a woman dies of cervical cancer. Globally, cancer of the cervix is the second most prevalent cancer in women, causing nearly 500,000 new cases per year, and the third leading cause of female cancer deaths after breast and lung cancer (Ferlay et al 2004).
There are over 100 types of human papillomavirus (HPV), of which 30-40 can infect mucosal tissue. The others cause a variety of non-genital conditions, such as plantar warts (Wilson 2001; Burd 2003; von Krogh 2001). Of the types that can infect mucosal tissue, there are low-risk HPV types that can cause benign, low-grade lesions on the cervical surface or genital warts (which rarely progress to cancer). More importantly, there are over 15 oncogenic types that have been directly linked to cervical cancer (Bosch et al 2002; Schiller and Davies 2004; Muñoz et al 2003). Of these oncogenic HPV types, HPV 16 and 18 are the most important and are found in over 70% of cervical cancers globally (Muñoz et al 2004).
HPV is a very common and easily transmittable virus. The risk of contracting HPV starts with the first sexual encounter and lasts throughout a woman’s sexually active life. Infection does not require full penetrative intercourse, as skin-to-skin contact in the genital area is enough to spread the infection. Condoms do not fully protect from cervical cancer (Schiffman and Kjaer 2003; Burd 2003).
Virtually all cases of cervical cancer are associated with HPV infection (Bosch et al 2002).
Given the significant burden associated with cervical cancer, prevention and treatment strategies are critical (Franceschi 2005; Franco et al 2001). Proper screening requires well-organised acquisition of cervical samples at regular intervals (Sankaranarayanan et al 2005). This identifies abnormal cells on the cervix, which can be removed, if treatment is necessary.
Cervical screening is currently the only strategy for early detection of cervical abnormalities and HPV infections.
Enter the HPV & Cervical Cancer Knowledge Centre
What’s in the HPV & Cervical Cancer Knowledge Centre?
- Overview
- Human papillomavirus (HPV)
- Natural History of HPV
- HPV Transmission and Acquisition
- Cervical Cancer Risk Factors
- From Oncogenic HPV to Cervical Cancer
- Immunology of HPV Infection
- Virology
- The Character of HPV
- HPV and Cervicalcancer
- Other Disease Caused by HPV
- Epidemiology
- Geography
- Cervical Cancer and Age
- Lifetime Risk of Cervical Cancer
- The Cervix
- Anatomy
- Cell Biology
- Immunology of the Cervix
- Impact of abnormal screening results, pre-cancerous lesions and cervical cancer
- Impact of abnormal screening results, pre-cancerous lesions and cervical cancer on quality of life (QoL)
- Impact of Cervical Cancer on Years of Life Lost (YLL)
- Societal costs of pre-cancerous lesions and Cervical Cancer
- Prevention & Treatment of oncogenic HPV and cervical cancer
- Screening for Cervical Cancer
- Impact of Abnormal Screening Results
- Treatment of CIN and Cervical Cancer
- Prevention of Cervical Cancer where screening not implemented
- Frequently Asked Questions
- References
- Acetowhitening
- Adenocarcinoma
- Age-standardised
- Antibody
- Antigen / Antigenic
- Base pairs
- Biopsy
- Brachytherapy
- Capsid
- Cell-mediated
- Cervical screening
- Chemotherapy
- CIN
- CIS
- Colposcope
- Co-morbid
- Cryotherapy
- Cytokines
- Cytotoxic
- Dysplasia / dysplasias
- Dysplastic
- Envelope
- Epidemiology / epidemiological
- Epithelial cells/epithelium
- False negative
- G1 phase
- Genome
- Homology
- HPV
- HSIL
- Humoral
- Hysterectomy
- IgG (antibody)
- Incidence/incidences
- Lesions A general term to describe an area of abnormal tissue
- Liquid-based cytology
- LSIL
- Limphangiogram
- Menopause
- Metaplastic/metaplasia
- Metastasized
- Mortality
- Neoplastic
- Odds ratio
- Oncogenesis
- Oncogenic
- Oncogenic transformation
- Pap
- Parity
- Persistent
- Phylogenetics
- Primary prevention
- Promoter
- Radiotherapy / Ionising radiation
- Stages
- Transcription
- Transient
- Transformation zone
- Triage
- Tumour
- Vaccination
- Vascularisation
- Viraemia
- Virion
- X-rays
- Years of life lost (YLL)
-
CERVARIX - 51.32%
CERVARIX is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. The indication is based on demonstration of efficacy in women aged 15-25 years following vaccination with ... -
GARDASIL - 51.32%
Gardasil is a vaccine for the prevention of premalignant genital lesions (cervical, vulvar and vaginal), cervical cancer and external genital warts (condyloma acuminata) causally related to Human Papillomavirus (HPV) types 6, 11, 16 and 18. The indication is based on the demonstration of efficacy of ... -
Cisplatin - 41.35%
Cisplatin has antitumour activity either as a single agent or in combination chemotherapy particularly in the treatment of testicular and metastatic ovarian tumours, also cervical tumours, lung carcinoma and bladder cancer ... -
Gemcitabine 200mg Powder for Solution for Infusion - 26.38%
Bladder Cancer: Locally advanced or metastatic bladder cancer in combination with cisplatin. Breast Cancer: Locally advanced or metastatic breast cancer in combination with paclitaxel in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. The preceding chemotherapy should have ... -
Mitomycin - 26.21%
... agent and in combination in liver cancer when given by the intra-arterial route. 6. It has a possible role in combination with other cytotoxic drugs in colo-rectal cancer. 7. It shows a degree of activity as a single agent or part of combination therapy in cancer of the head and neck. 8. It shows a ... -
TAXOTERE - 25.58%
... cancer TAXOTERE in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. TAXOTERE in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer ...

Medical News